Skip to main content
Retour
GMAB logo

Genmab A/S

Qualité des données : 100%
Survendu
GMAB
NASDAQ Healthcare Biotechnology
25,68 €
▲ 0,58 € (2,31%)
Cap. Boursière : 15,86B
Également cotée sous GNMSF OTC
Fourchette du Jour
25,60 € 26,25 €
Fourchette 52 Semaines
17,24 € 35,43 €
Volume
1 318 372
Moyenne 50J / 200J
30,31 € / 27,96 €
Clôture Précédente
25,10 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E 2,6 0,4
P/B 0,4 2,9
ROE % 16,6 3,7
Net Margin % 25,9 3,8
Rev Growth 5Y % 29,6 10,0
D/E 1,0 0,2

Points Clés

Revenue grew 29,58% annually over 5 years — strong growth
Earnings declined -21,69% over the past year
ROE of 16,63% — decent returns on equity
Net margin of 25,89% shows strong profitability
Generating 7,33B in free cash flow
P/E of 2,58 — trading at a low valuation

Croissance

Revenue Growth (5Y)
29,58%
Revenue (1Y)10,23%
Earnings (1Y)-21,69%
FCF Growth (3Y)2,29%

Qualité

Return on Equity
16,63%
ROIC8,24%
Net Margin25,89%
Op. Margin33,60%

Sécurité

Debt / Equity
0,95
Current Ratio2,02
Interest Coverage20,49

Valorisation

P/E Ratio
2,58
P/B Ratio0,43
EV/EBITDA5,06
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 10,23% Revenue Growth (3Y) 20,01%
Earnings Growth (1Y) -21,69% Earnings Growth (3Y) 18,80%
Revenue Growth (5Y) 29,58% Earnings Growth (5Y) 20,05%
Profitability
Revenue (TTM) 23,73B Net Income (TTM) 6,14B
ROE 16,63% ROA 7,50%
Gross Margin 91,69% Operating Margin 33,60%
Net Margin 25,89% Free Cash Flow (TTM) 7,33B
ROIC 8,24% FCF Growth (3Y) 2,29%
Safety
Debt / Equity 0,95 Current Ratio 2,02
Interest Coverage 20,49 Dividend Yield 0,00%
Valuation
P/E Ratio 2,58 P/B Ratio 0,43
P/S Ratio 0,67 PEG Ratio -1,06
EV/EBITDA 5,06 Dividend Yield 0,00%
Market Cap 15,86B Enterprise Value 40,31B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 23,73B 21,53B 16,47B 14,51B 8,42B
Net Income 6,14B 7,84B 4,35B 5,45B 2,96B
EPS (Diluted) 9,79 12,14 6,60 8,26 4,48
Gross Profit 21,76B 20,54B 16,25B 14,51B 8,42B
Operating Income 7,97B 6,70B 5,32B 6,27B 2,95B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 81,86B 45,81B 35,29B 30,12B 24,63B
Total Liabilities 44,68B 9,11B 3,68B 2,84B 2,43B
Shareholders' Equity 37,18B 36,70B 31,61B 27,28B 22,20B
Total Debt 35,36B 1,03B 770,00M 597,00M 425,00M
Cash & Equivalents 10,91B 9,86B 14,87B 9,89B 8,96B
Current Assets 18,35B 27,85B 33,14B 28,22B 22,74B
Current Liabilities 9,07B 5,31B 2,48B 1,82B 1,57B

Scores de Stratégies

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#157 of 1024
65
Custom Capital Light Compounder
#138 of 213
34
Growth Price/Sales Ratio Focus (Ken Fisher)
#212 of 616
46
Custom Contrarian Investing (David Dreman)
#378 of 658
24

Activité Récente

Entré Cash Flow Compounder
Mar 24, 2026
Entré Capital Light Compounder
Mar 24, 2026
Entré Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entré Contrarian Investing (David Dreman)
Mar 24, 2026